Women’s health goes beyond mother & childcare. For instance, women has a higher risk of cardiovascular diseases compared to men, hence there is a need to invest more on addressing the biological differences in mainstream disease studies to ensure a more effective, personalised treatment. In addition, big data & AI application on female subjects may also differ from male subjects, prompting a need to investigate how studies should be developed differently in the future. This panel brings experts to debate and discuss how femtech is shaping to be the next global pharma focus and the new areas of focus in women's healthcare.
Moderator: Reenita Das, Partner, Frost & Sullivan
Evelyn Pang, Head Of Operations, Sanofi Pasteur
Marcel Van Duin, VP Research, Therapeutic Area Head, Reproductive Medicine & Women's Health, Ferring Pharmaceuticals